FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 354:2689-2695 June 22, 2006 Number 25 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text PowerPoint Slide Set Editorial by Jarcho, J. A. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

This Journal feature begins with a case vignette that includes a therapeutic recommendation. A discussion of the clinical problem and the mechanism of benefit of this form of therapy follows. Major clinical studies, the clinical use of this therapy, and potential adverse effects are reviewed. Relevant formal guidelines, if they exist, are presented. The article ends with the authors' clinical recommendations.

A 16-year-old boy with a 15-year history of asthma from the age of one year and two visits to the emergency department in the past year presents for evaluation. He reports symptoms consistent with those of severe persistent asthma . . . [Full Text of this Article]

The Clinical Problem

Treatment

Effect of Therapy with Omalizumab

Evidence of a Clinical Benefit

Clinical Use

Preparation for Use

Cost

Response to Treatment

Adverse Effects

Areas of Uncertainty

Guidelines

Recommendations

Source Information

From the Department of Pediatrics, Washington University School of Medicine, St. Louis.

Related Letters:

Omalizumab for Asthma
Winchester D. E., Jacob A., Murphy T., Tonnel A.-B., Tillie-Leblond I.
Extract | Full Text | PDF  
N Engl J Med 2006; 355:1281-1282, Sep 21, 2006. Correspondence

This article has been cited by other articles:

• Massanari, M., Milgrom, H., Pollard, S., Maykut, R.J., Kianifard, F., Fowler-Taylor, A., Geba, G.P., Zeldin, R.K. (2009). Adding Omalizumab to the Therapy of Adolescents With Persistent Uncontrolled Moderate--Severe Allergic Asthma. CLIN PEDIATR 48: 859-865 [Abstract]  
• Ota, T., Aoki-Ota, M., Duong, B. H., Nemazee, D. (2009). Suppression of IgE B Cells and IgE Binding to Fc{epsilon}RI by Gene Therapy with Single-Chain Anti-IgE. J. Immunol. 182: 8110-8117 [Abstract] [Full Text]  
• Lemanske, R. F. Jr. (2009). Asthma Therapies Revisited: What Have We Learned?. Proc Am Thorac Soc 6: 312-315 [Abstract] [Full Text]  
• Bousquet, J., Wahn, U., Meltzer, E. O., Fox, H., Hedgecock, S., Thomas, K., Fowler-Taylor, A. (2008). Omalizumab: an anti-immunoglobulin E antibody for the treatment of allergic respiratory diseases. ERR 17: 1-9 [Abstract] [Full Text]  
• Reddy, R C (2008). Severe asthma: approach and management. Postgrad. Med. J. 84: 115-120 [Abstract] [Full Text]  
• Townshend, J, Hails, S, Mckean, M (2007). Management of asthma in children. BMJ 335: 253-257 [Full Text]  
• Frankel, S. K., Groshong, S. D., Lynch, D. A. (2007). Invited Commentary. RadioGraphics 27: 637-639 [Full Text]  
• Winchester, D. E., Jacob, A., Murphy, T., Tonnel, A.-B., Tillie-Leblond, I. (2006). Omalizumab for asthma.. NEJM 355: 1281-1282 [Full Text]